Medical cannabis company, AusCann (ASX:AC8) has announced its Chilean partner Fundacion Daya has established a scheme which enables immediate access for Chilean patients to medicinal cannabis.
The special access scheme allows doctors to prescribe medicinal cannabis to patients prior to completion of current trials for product registration.
A similar access scheme is used in Australia, prescriptions are approved on a case by case basis.
The process enables access to the products while clinical trials are being completed.
The company says the access scheme will accelerate the goal of supplying final dose form medicines for pain treatment in Latin America.
Shares in AusCann (ASX:AC8) are trading flat at $1.62.